Harrow (HROW) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Harrow (HROW) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 21.8% versus a loss of 67.4%. Mineralys Therapeutics is the larger company by market cap ($1.21 billion vs $1.14 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | MLYS |
|---|---|---|
| Share price | $30.41 | $13.66 |
| Market cap | $1.14B | $1.21B |
| 1-day change | -5.35% | -3.53% |
| YTD return | -37.94% | -62.36% |
| 1-year return | -21.85% | -67.38% |
| 5-year return | +196.11% | — |
| Forward P/E | 16.26 | — |
| EPS (TTM) | $-0.76 | $-4.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $272.30M | — |
| Revenue growth (YoY) | +36.41% | — |
| Net income (latest FY) | $-5.14M | $-154.65M |
| Gross margin | 75.05% | — |
| Operating margin | 11.21% | — |
| Net margin | -1.89% | — |
| 52-week high | $54.85 | $44.13 |
| 52-week low | $25.76 | $13.57 |
| Distance from 52-week high | -44.56% | -69.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +104.70% | +218.89% |
| Average volume | 626.20K | 1.55M |
| Shares outstanding | 37.53M | 88.56M |
| Employees | 373 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HROW has outperformed MLYS by 45.5 percentage points over the past year.
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
HROW vs MLYS FAQ
Which is bigger, Harrow or Mineralys Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.21B compared with $1.14B for Harrow (HROW).
Which stock has performed better over the past year, HROW or MLYS?
HROW returned -21.85% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Harrow and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.